Allele Loss at the Human GPA Locus: A Model for Recessive Oncogenesis with Potential Clinical Application
Publication Date / Copyright Date
We have derived an in vivo assay, based on loss of heterozygosity at the human glycophorin A locus, to identify and quantitate variant erythrocytes arising by the same mechanisms of mutation and segregation that are responsible for recessive oncogenesis. With the current assay, which involves immunolabeling of whole blood with fluorescence–conjugated allele-specific monoclonal antibodies followed by flow cytometric analysis, two classes of variants are distinguishable: simple allele loss variants, and variants arising by loss of one allele and duplication of the remaining homologue. This assay has important clinical implications as a biodosimeter to measure exposure to genotoxic agents; it may also provide a means of estimating cancer risk, especially the risk of recurrence after childhood cancer.
Medical Specialties | Medicine and Health Sciences | Osteopathic Medicine and Osteopathy
Grant, Stephen G.; Bigbee, William L.; Langlois, Richard G.; and Jensen, Ronald H., "Allele Loss at the Human GPA Locus: A Model for Recessive Oncogenesis with Potential Clinical Application" (1991). Faculty Articles. 583.